ESPE2022 Poster Category 1 Adrenals and HPA Axis (52 abstracts)
Agreement between Acth-low test and Insuline Tolerance Test in Patients with Risk Factors for Central Adrenal Insufficiency
1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (D.I.N.O.G.M.I.), University of Genova, Genova, Italy; 2Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genova, Italy
Background: Central adrenal insufficiency(CAI) is a potential life-threatening condition and a prompt diagnosis represents a clinical challenge; indeed, the Insulin Tolerance Test(ITT), gold standard for CAI diagnosis, can be contraindicated in some conditions. Aims were to evaluate the diagnostic value of the ACTH low test(ACTH-LT) compared to the ITT and to identify eventual determinants(primary diagnosis, risk factors, symptoms, baseline cortisol, hypothalamic-pituitary defects) as predictors of a pathological cortisol peak.
Methods: 64 patients(n=41males, n=23females) underwent ITT and ACTH-LT between 2010 and 2021(mean distance 18months) for suspected CAI. According to primary diagnosis, patients were categorized as: tumoral(n=29), multiple-pituitary defects(n=16), idiopathic GHD(n=12), others(n=7). Exclusion criteria were distance between the tests>8years, being on GC therapy, insulin resistance, failure to halve glycemia after ITT. Risk factors considered were brain surgery, brain radiotherapy and prolonged glucorticoids-GC administration. Potential CAI symptoms were defined as asthenia, recurrent headache and/or fatigue. Baseline characteristics are summarized in Table 1.
Results: Thirty-nine patients had pathological cortisol peak values at the ITT(<18µg/dL);ACTH-LT was pathological in 18/39(<16µg/dL), borderline in 14/39(16-22µg/dL) and normal in 7/39. Agreement between ACTH-LT and ITT was 0.83(Cohen’s K 0.51,95% CI:0.26-0.75), with a sensitivity of 88%(44/50), a specificity of 64%(9/14), a positive predictive value of 0.89(44/49) and a negative predictive value of 0.60(9/15). Peak cortisol levels to ACTH-LT were lower in patients with symptoms compared to subjects without them [15.2(IQR 11.3-18.3µg/dL) vs 17.7(IQR 14.5-19.8µg/dL), P=0,017]. No significant differences were found between ITT and ACTH-LT cortisol peak values in pubertal/prepubertal children, subjects with or without risk factors and different primary diagnosis.
Characteristics | n.(%) | Median[1st–3rd quartile] |
Pre-pubertal at ITT | 13(20.3%) | |
Post-pubertal at ITT | 51(79.7%) | |
Age at ACTH-LT(years) | 13.9[12.8-16.6] | |
BMI-SDS at ACTH-LT | 1.0[0.3–2.0] | |
Baseline cortisol(µg/dL) | 9.9[8.0–13.0] | |
Cortisol peak(µg/dL) | 18.2[15.2-21.3] | |
Cortisol peak yes-symptoms(µg/dL) | 15.6[13.4-19.1] | |
Cortisol peak no-symptoms(µg/dL) | 18.6[15.8-22.1] | |
Age at ITT (years) | 14.6[12.2-16.9] | |
BMI-SDS at ITT | 0.9[0.2–2.0] | |
Baseline cortisol(µg/dL) | 9.3[6.9-13.5] | |
Cortisol peak(µg/dL) | 16.9[13.8-19.4] | |
Risk Factors | 45(70.3%) | |
Symptoms | 17(26.6%) |
Conclusion: Preliminary results demonstrate that the ACTH-LT is suitable for screening purposes, but not for final confirmation of CAI in our cohort. Further studies are needed to better define which factors influence the ACTH-LT response and its diagnostic value for clinicians.